Early identification of high-risk pregnancies remains a crucial goal in modern maternal healthcare. Clinicians worldwide are shifting towards more advanced algorithms to predict complications. Specifically, preterm preeclampsia screening has evolved from basic risk checklist methods to advanced biomarker models. A recent cost-effectiveness study in the United Kingdom evaluated the Fetal Medicine Foundation (FMF) strategy against traditional approaches. Moreover, this analysis demonstrates significant clinical benefits and substantial economic savings for healthcare systems. Consequently, adopting these advanced algorithms can revolutionize maternal care protocols.

FMF vs NICE in Preterm Preeclampsia Screening

The National Institute for Health and Care Excellence (NICE) guidelines rely mostly on maternal risk factors. In contrast, the FMF strategy utilizes a multivariable approach. This model combines maternal history, mean arterial pressure, uterine artery pulsatility index, and placental growth factor. Consequently, researchers simulated 10,000 pregnant patients to compare these two protocols. The FMF strategy identified high-risk patients and recommended 150 mg of daily aspirin until 36 weeks. Ultimately, the results showed that the FMF model is both clinically superior and highly cost-effective.

Economic Impact and Clinical Outcomes

The simulation demonstrated highly favorable economic metrics. For every 10,000 screened patients, the FMF strategy generated a cost-saving of £3,191. Furthermore, it achieved a quality-adjusted life year (QALY) gain of 0.92, showing a dominant incremental cost-effectiveness ratio. The model also saved £199 for each avoided case of preterm preeclampsia. Additionally, this strategy remained highly cost-effective across various scenarios of disease incidence and patient adherence. Therefore, clinical guidelines should prioritize this multivariable screening method over traditional checklists.

Global Relevance and Implementation

These findings carry immense relevance for obstetricians globally, including in South Asia. In India, preeclampsia remains a major contributor to maternal and neonatal morbidity. Because the FMF algorithm performs well in South Asian populations, local adoption could significantly improve outcomes. However, implementing this model requires structured ultrasound training and biochemically standardized assays. Therefore, healthcare providers must invest in the infrastructure to support this screening. As a result, many private and public health facilities are currently transitioning to this superior protocol.

Frequently Asked Questions

Q1: What is the primary difference between the FMF and NICE screening strategies?

The NICE strategy relies mostly on checklists of maternal risk factors. In contrast, the FMF strategy utilizes a multivariable approach. It combines maternal risk factors with mean arterial pressure, uterine artery Doppler, and placental growth factor.

Q2: Why is the FMF strategy considered cost-effective?

The FMF strategy identifies high-risk patients more accurately. Consequently, targeting preventive aspirin therapy reduces the incidence of preterm preeclampsia, which saves significant clinical and hospital costs.

Q3: Can these screening findings be applied to South Asian patients?

Yes, studies show the FMF algorithm performs well in South Asian populations. However, clinicians may need to adjust biomarker medians for the local demographic to optimize detection rates.

References

Ani MA et al. First Trimester Screening for Preterm Preeclampsia in the United Kingdom: A Cost-Effectiveness Analysis. BJOG. 2026 Jul 01. doi: 10.1111/1471-0528.70294. PMID: 42383395.
Guerby P et al. Prospective Validation of First-Trimester Screening for Preterm Preeclampsia in Nulliparous Women (PREDICTION Study). Hypertension. 2024 Jul;81(7):1574-1582. doi: 10.1161/HYPERTENSIONAHA.123.22584.
Wright D, Tan MY. Serum PlGF compared to PAPP-A in first trimester screening for preterm preeclampsia. BJOG. 2022 Feb;129(3):428-435.